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Background
Dual antiplatelet therapy is recommended after coronary stenting to prevent throm-
botic complications, yet the benefits and risks of treatment beyond 1 year are uncertain.
Methods
Patients were enrolled after they had undergone a coronary stent procedure in which 
a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine 
drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to con-
tinue receiving thienopyridine treatment or to receive placebo for another 18 months; 
all patients continued receiving aspirin. The coprimary efficacy end points were stent 
thrombosis and major adverse cardiovascular and cerebrovascular events (a compos-
ite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. 
The primary safety end point was moderate or severe bleeding.
Results
A total of 9961 patients were randomly assigned to continue thienopyridine treat-
ment or to receive placebo. Continued treatment with thienopyridine, as compared 
with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 
0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse car-
diovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 
0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thieno-
pyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). 
The rate of death from any cause was 2.0% in the group that continued thienopyri-
dine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; 
P = 0.05). The rate of moderate or severe bleeding was increased with continued thi-
enopyridine treatment (2.5% vs. 1.6%, P = 0.001). An elevated risk of stent thrombo-
sis and myocardial infarction was observed in both groups during the 3 months 
after discontinuation of thienopyridine treatment.
Conclusions
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as 
compared with aspirin therapy alone, significantly reduced the risks of stent throm-
bosis and major adverse cardiovascular and cerebrovascular events but was associated 
with an increased risk of bleeding. (Funded by a consortium of eight device and drug 
manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.)
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Millions of patients worldwide undergo coronary stenting each year for the treatment of ischemic heart dis-
ease.1,2 Although drug-eluting stents reduce the 
rate of restenosis as compared with bare-metal 
stents, there is concern that drug-eluting stents 
may be associated with a risk of stent thrombosis 
beyond 1 year after treatment.3 Stent thrombosis 
is rare, yet it is frequently associated with myocar-
dial infarction and may be fatal.3 Furthermore, 
ischemic events, such as myocardial infarction, 
stroke, or death from cardiovascular causes, that 
are unrelated to the treated coronary lesion may 
also occur beyond 1 year.4,5
The use of dual antiplatelet therapy in which 
a P2Y12-receptor inhibitor is combined with as-
pirin is critically important for the prevention of 
coronary stent thrombosis, and this therapy is 
currently recommended for 6 to 12 months after 
implantation of a drug-eluting stent.6,7 Although 
some observational studies suggest that extend-
ing dual antiplatelet therapy beyond 1 year is 
associated with a reduced risk of myocardial 
infarction after the placement of a drug-eluting 
stent,8 several trials have shown an increased 
risk of bleeding without a reduction in the inci-
dence of myocardial infarction with longer ther-
apy.9-12 Whether treatment with dual antiplatelet 
therapy beyond 1 year reduces the rate of either 
coronary-stent thrombosis or ischemic events 
occurring in an area remote from the stent has 
not been determined by an adequately powered, 
randomized trial.
The Dual Antiplatelet Therapy (DAPT) study 
was an international, multicenter, randomized, 
placebo-controlled trial that was designed to 
determine the benefits and risks of continuing 
dual antiplatelet therapy beyond 1 year after the 
placement of a coronary stent.
Me thods
Study Design
The design of the DAPT study has been described 
previously.13 The trial was designed in response 
to a request from the Food and Drug Administra-
tion (FDA) to manufacturers of coronary stents and 
was conducted under an investigational-device ex-
emption through a public–private collaboration 
involving the FDA, eight stent and pharmaceuti-
cal manufacturers who funded the study (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org), and the Harvard 
Clinical Research Institute (HCRI). The stent 
manufacturers who funded the trial had contrib-
uting roles in the design of the trial and in the 
collection of the data, as detailed in the Supple-
mentary Appendix. The HCRI was responsible 
for the scientific conduct of the trial and an inde-
pendent analysis of the data.
To facilitate enrollment, a single, uniform 
randomized trial was designed that incorporated 
five individual component studies (see the Sup-
plementary Appendix). Patients were enrolled in 
the trial either by the HCRI or through one of 
four postmarketing surveillance studies that 
were designed to collect similar clinical data in 
similar patient populations. Each contributing 
study followed uniform randomization criteria 
and the same follow-up schedule for assessments, 
as specified by the overall DAPT study protocol. 
A single clinical-events committee whose mem-
bers were unaware of the group assignments ad-
judicated events, and an unblinded, independent, 
central data and safety monitoring committee 
oversaw the safety of all patients. The institu-
tional review board at each participating institu-
tion approved the study.
The first three authors and the last author 
wrote the manuscript under the coordination of 
the HCRI, had full access to the data, and vouch 
for the integrity of the analyses presented and 
for the fidelity of this report to the trial protocol 
(available at NEJM.org). The manuscript was 
provided to the funding manufacturers for re-
view in advance of publication; however, they did 
not have the right to make changes, except with 
regard to individual manufacturer confidential 
information.
Study Population
We enrolled patients older than 18 years of age 
who were candidates for dual antiplatelet therapy 
after treatment with FDA-approved drug-eluting 
or bare-metal stents. Details of the inclusion and 
exclusion criteria are provided in the Supplemen-
tary Appendix. Each patient provided written in-
formed consent at the time of enrollment.
The population included in the primary anal-
ysis for this report comprised only patients who 
were treated with drug-eluting stents (results in 
patients who received bare-metal stents are not 
included in this analysis) (Fig. 1). Drug-eluting 
stents included sirolimus-eluting stents (Cypher, 
Cordis), zotarolimus-eluting stents (Endeavor, Med-
tronic), paclitaxel-eluting stents (TAXUS, Boston 
A video summary 
is available at 
NEJM.org 
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22,866 Had received drug-eluting stents
25,682 Patients who had received a 
stent were enrolled
2816 Had received bare-metal stents
9961 Underwent randomization at 12 mo
5261 Were not eligible
14 Did not meet enrollment criteria
2638 Had events
293 Died
575 Had myocardial infarction
186 Had stroke
108 Had stent thrombosis
1620 Had revascularization
616 Had severe or moderate
GUSTO bleeding
1144 Were nonadherent
1465 Had other exclusion criteria
7644 Were eligible but did not undergo
randomization
5808 Withdrew consent
1745 Had randomization visit out of time
window or were lost to follow-up
36 Had other reasons
55 Had unknown reason
5020 Were assigned to receive aspirin
plus thienopyridine
4941 Were assigned to receive aspirin
plus placebo
237 Were excluded
132 Withdrew consent
88 Were lost to follow-up
17 Were not available for
follow-up
 225 Were excluded
116 Withdrew consent
91 Were lost to follow-up
18 Were not available for
follow-up
4783 (95.3%) Were included in clinical
follow-up at 30 mo
4716 (95.4%) Were included in clinical
follow-up at 30 mo
51 Were excluded
9 Withdrew consent
34 Were lost to follow-up
8 Were not available for
follow-up
58 Were excluded
12 Withdrew consent
42 Were lost to follow-up
4 Were not available for
follow-up
4732 (94.3%) Were included in clinical
follow-up at 33 mo
4658 (94.3%) Were included in clinical
follow-up at 33 mo
Figure 1. Enrollment, Randomization, and Follow-up.
Patients were enrolled within 72 hours after stent placement. They were followed for 12 months while they received open- 
label treatment with thienopyridine plus aspirin and were then randomly assigned to receive thienopyridine therapy or place-
bo (each in addition to aspirin) for an additional 18 months. The randomized treatment period ended at 30 months; thereaf-
ter, patients continued taking aspirin only and were followed for another 3 months. Although the number of patients with 
available data on clinical follow-up is reported in each group, the coprimary efficacy end points were analyzed with the 
last available follow-up information in the intention-to-treat population, which included all patients who underwent ran-
domization. GUSTO denotes Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
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Table 1. Characteristics of Patients Who Were Treated with Drug-Eluting Stents and Who Underwent Randomization.*
Characteristic
Continued Thienopyridine 
(N = 5020)
Placebo
(N = 4941)
Patients
Age — yr 61.8±10.2 61.6±10.1
Female sex — no. (%) 1242 (24.7) 1284 (26.0)
Nonwhite race — no./total no. (%)† 438/4918 (8.9) 419/4847 (8.6)
Hispanic or Latino ethnic group — no./total no. (%)† 159/4924 (3.2) 159/4847 (3.3)
Weight — kg‡ 91.5±19.7 91.5±19.4
Body-mass index§ 30.5±5.8 30.6±5.8
Diabetes mellitus — no./total no. (%) 1556/5006 (31.1) 1481/4927 (30.1)
Hypertension — no./total no. (%) 3796/5006 (75.8) 3649/4934 (74.0)
Current cigarette smoker or within past year — no./total no. (%) 1222/4965 (24.6) 1210/4893 (24.7)
Stroke or TIA — no./total no. (%) 155/5006 (3.1) 169/4931 (3.4)
Congestive heart failure — no./total no. (%) 238/5001 (4.8) 223/4926 (4.5)
Peripheral arterial disease — no./total no. (%) 284/4937 (5.8) 284/4857 (5.8)
Prior PCI — no./total no. (%) 1518/4995 (30.4) 1529/4928 (31.0)
Prior CABG — no./total no. (%) 568/5012 (11.3)  581/4930 (11.8)
Prior myocardial infarction — no./total no. (%) 1092/4953 (22.0) 1026/4870 (21.1)
Indication for PCI — no. (%)
STEMI 534 (10.6) 511 (10.3)
NSTEMI 776 (15.5) 767 (15.5)
Unstable angina¶ 838 (16.7) 825 (16.7)
Stable angina 1882 (37.5) 1870 (37.8)
Other 990 (19.7) 968 (19.6)
Any risk factor for stent thrombosis — no./total no. (%)‖ 2410/4751 (50.7) 2389/4685 (51.0)
Region — no. (%)
North America 4502 (89.7) 4416 (89.4)
Europe 402 (8.0) 405 (8.2)
Australia or New Zealand 116 (2.3) 120 (2.4)
Thienopyridine drug at start of open-label period — no. (%)**
Clopidogrel 3275 (65.2) 3230 (65.4)
Prasugrel 1745 (34.8) 1711 (34.6)
Type of drug-eluting stent at index procedure — no. (%)
Everolimus-eluting 2345 (46.7) 2358 (47.7)
Paclitaxel-eluting 1350 (26.9) 1316 (26.6)
Zotarolimus-eluting 642 (12.8) 622 (12.6)
Sirolimus-eluting 577 (11.5) 541 (10.9)
>1 type 106 (2.1) 104 (2.1)
No. of treated lesions 1.30±0.55 1.29±0.54
No. of treated vessels 1.11±0.33 1.12±0.34
No. of stents 1.47±0.75 1.45±0.75
Minimum stent diameter — no. (%)
<3 mm 2341 (46.6) 2293 (46.4)
≥3 mm 2679 (53.4) 2648 (53.6)
Total stent length — mm 27.70±16.77 27.43±17.02
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Scientific), and everolimus-eluting stents (Xience, 
Abbott Vascular; and Promus, Boston Scientific). 
It was recommended that all patients receive either 
clopidogrel at a maintenance dose of 75 mg daily 
or prasugrel at a maintenance dose of 10 mg 
daily (with a dose of 5 mg daily recommended 
in patients who weighed less than 60 kg).13 The 
recommended maintenance dose of aspirin was 
75 to 162 mg daily, to be taken indefinitely.
Study Procedures
Patients were enrolled within 72 hours after place-
ment of a stent and were given open-label aspirin 
and thienopyridine for 12 months. At 12 months, 
patients who had not had a major adverse cardio-
vascular or cerebrovascular event, repeat revascu-
larization, or moderate or severe bleeding and 
had been adherent to thienopyridine therapy (de-
fined as having taken 80 to 120% of the drug 
without an interruption of longer than 14 days) 
were eligible for randomization (Fig. 1).
Eligible patients continued taking aspirin and 
were randomly assigned, in a 1:1 ratio, to contin-
ued thienopyridine therapy or to placebo for an 
additional 18 months (months 12 to 30 after en-
rollment). A computer-generated randomization 
schedule stratified patients according to the type of 
stent they had received (drug-eluting vs. bare-met-
al), hospital site, type of thienopyridine drug, and 
presence or absence of at least one prespecified 
clinical or lesion-related risk factor for stent throm-
bosis (see Table S1 in the Supplementary Appen-
dix).13 After the end of the randomized treatment 
period, we followed patients for a 3-month obser-
vational period during which they took aspirin 
alone (months 30 to 33 after enrollment) so that 
we could assess the effect of discontinuation of 
thienopyridine on the rates of end-point events.
Table 1. (Continued.)
Characteristic
Continued Thienopyridine 
(N = 5020)
Placebo
(N = 4941)
Lesions
Treated vessel††
Native coronary-artery lesions 6396/6586 (97.1) 6204/6407 (96.8)
Left main  55/6586 (0.8) 55/6407 (0.9)
Left anterior descending 2715/6586 (41.2) 2586/6407 (40.4)
Right 2153/6586 (32.7) 2057/6407 (32.1)
Circumflex 1473/6586 (22.4) 1506/6407 (23.5)
Venous graft 154/6586 (2.3) 173/6407 (2.7)
Arterial graft  36/6586 (0.5) 30/6407 (0.5)
Modified ACC–AHA lesion class B2 or C — no./total no. (%)‡‡ 2754/6335 (43.5) 2643/6137 (43.1)
* Plus–minus values are means ±SD. There were no significant differences between the two groups except with respect 
to hypertension (P = 0.03). For most variables, 0 to 3% of the patients had missing values; however, 3.5% of the pa-
tients were missing data on lesion class. CABG denotes coronary-artery bypass grafting, NSTEMI non–ST-segment el-
evation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial in-
farction, and TIA transient ischemic attack.
† Race and ethnic group were self-reported.
‡ Data on body weight were available for 5009 patients in the group that was randomly assigned to continued thieno-
pyridine therapy and 4931 in the group that was assigned to placebo.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters. Data were available for 
4973 in the group that was randomly assigned to continued thienopyridine therapy and 4901 in the group that was 
assigned to placebo.
¶ This category included unstable angina without reported elevation of cardiac enzymes.
‖ Risk factors for stent thrombosis are listed in Table S1 in the Supplementary Appendix.
** At the time of randomization (12 months after the start of the open-label period), 63.5% of the patients who were 
subsequently assigned to continue receiving thienopyridine were taking clopidogrel, and 34.7% were taking prasug-
rel; the corresponding rates among the patients who were subsequently assigned to the placebo group were 65.2% 
and 34.8%.
†† A total of 6594 lesions were treated in the thienopyridine group and 6413 in the placebo group.
‡‡ The definitions of class B2 and class C lesions according to the modified American College of Cardiology (ACC)–
American Heart Association (AHA) criteria are provided in the Supplementary Appendix.
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End Points
The coprimary efficacy end points were the cu-
mulative incidence of definite or probable stent 
thrombosis (as assessed according to the Academ-
ic Research Consortium definitions)14 and of ma-
jor adverse cardiovascular and cerebrovascular 
events (defined as the composite of death, myocar-
dial infarction, or stroke) during the randomized 
treatment period (month 12 to month 30). The pri-
mary safety end point was the incidence of mod-
erate or severe bleeding during this same period 
(as assessed according to the Global Utilization 
of Streptokinase and Tissue Plasminogen Activator 
for Occluded Arteries [GUSTO] criteria).15 Bleed-
ing was also evaluated according to the Bleeding 
Academic Research Consortium (BARC) criteria.16 
More detailed definitions of the end points are 
provided in the Supplementary Appendix. After the 
primary analysis had been completed, a second 
clinical-events committee whose members were 
unaware of the treatment assignment was con-
vened to adjudicate noncardiovascular causes of 
death.
Statistical Analysis
The primary efficacy analysis was a superiority 
analysis performed with the use of the log-rank 
test, with stratification according to geographic 
region (North America, Europe, or Australia and 
New Zealand), thienopyridine drug received at the 
time of randomization, and presence or absence 
of risk factors for stent thrombosis. We controlled 
the two-sided family-wise error rate of 0.05 across 
the two coprimary end points using the Hochberg–
Benjamini method.17 With this method, the null 
hypothesis of randomized treatment equivalence 
is rejected if significance is achieved for both end 
points at a two-sided alpha level of 0.05 or for 
Table 2. Stent Thrombosis and Major Adverse Cardiovascular and Cerebrovascular Events.*
Outcome
Continued Thienopyridine 
(N = 5020)
Placebo 
(N = 4941)
Hazard Ratio,  
Thienopyridine vs. Placebo
(95% CI)† P Value†
no. of patients (%)
Stent thrombosis‡ 19 (0.4) 65 (1.4) 0.29 (0.17–0.48) <0.001
Definite 15 (0.3) 58 (1.2) 0.26 (0.14–0.45) <0.001
Probable 5 (0.1) 7 (0.1) 0.71 (0.22–2.23) 0.55
Major adverse cardiovascular and 
cerebrovascular events§
211 (4.3) 285 (5.9) 0.71 (0.59–0.85) <0.001
Death 98 (2.0) 74 (1.5) 1.36 (1.00–1.85) 0.05
Cardiac 45 (0.9) 47 (1.0) 1.00 (0.66–1.52) 0.98
Vascular 5 (0.1) 5 (0.1) 0.98 (0.28–3.39) 0.98
Noncardiovascular 48 (1.0) 22 (0.5) 2.23 (1.32–3.78) 0.002
Myocardial infarction 99 (2.1) 198 (4.1) 0.47 (0.37–0.61) <0.001
Stroke 37 (0.8) 43 (0.9) 0.80 (0.51–1.25) 0.32
Ischemic 24 (0.5) 34 (0.7) 0.68 (0.40–1.17) 0.16
Hemorrhagic 13 (0.3) 9 (0.2) 1.20 (0.50–2.91) 0.68
Type uncertain 0 1 (<0.1) — 0.32
* At 12 months after placement of a drug-eluting stent, patients were randomly assigned to receive either continued thi-
enopyridine therapy plus aspirin or placebo plus aspirin for 18 months. Data are presented for the intention-to-treat 
population. The primary analysis was performed on data from the period of 12 to 30 months after enrollment, and the 
study coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular 
events. Percentages are Kaplan–Meier estimates.
† The hazard ratios and P values were stratified according to geographic region (North America, Europe, or Australia and 
New Zealand), thienopyridine drug received at the time of randomization, and presence or absence of risk factors for 
stent thrombosis. P values were calculated with the use of a log-rank test.
‡ Definite and probable stent thrombosis were determined according to the criteria of the Academic Research Consortium.
§ The end point of major adverse cardiovascular and cerebrovascular events was a composite of death, myocardial infarc-
tion, or stroke.
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one end point at a two-sided alpha level of 0.025. 
We assumed that the annual event rates with pla-
cebo would be 0.5% for stent thrombosis and 
2.9% for major adverse cardiovascular and cere-
brovascular events, that the hazard ratios with 
continued thienopyridine therapy versus placebo 
would be 0.45 for stent thrombosis and 0.75 for 
major adverse cardiovascular and cerebrovascu-
lar events, and that the annual loss to follow-up 
would be no more than 3%. Given these assump-
tions, we calculated that with a sample of 9800 
patients undergoing randomization and receiv-
ing drug-eluting stents, the study would have at 
least 85% power for the superiority analysis. This 
sample size was reduced from the 12,196 specified 
in the original protocol because of changes made 
in statistical parameters before enrollment was 
completed and without inspection of the study data 
(as described in the Supplementary Appendix).
The primary safety analysis was a noninferiority 
analysis performed with the use of the Farrington–
Manning risk-difference approach.18 Assuming 
an annualized rate for moderate or severe bleed-
ing of 1.9% and an absolute noninferiority margin 
of 0.8%, at a one-sided alpha level of significance 
of 0.025, we calculated that a sample size of 9960 
patients would give the study 80% power to detect 
noninferiority.
The primary analyses of major adverse car-
diovascular and cerebrovascular events and stent 
thrombosis were performed on data from all pa-
tients who underwent randomization and were 
treated with drug-eluting stents (the intention-to-
treat population). Kaplan–Meier estimates of the 
cumulative incidence of each end point are pre-
sented according to study group, with two-sided 
95% confidence intervals of stratified hazard ra-
tios. Data for patients who did not have an end-
point event were censored for the analysis of that 
end point at the time of the last known contact 
or at 30 months, whichever was earlier. Secondary 
analyses included an examination of the same 
end points in all the patients over the course of 
the 21-month postrandomization period, the last 
3 months of which the patients were not receiving 
the randomized treatment, and hazards before 
and after discontinuation of the study drug were 
assessed for qualitative differences.
The primary noninferiority assessment of bleed-
ing was performed on data from patients who 
underwent randomization, were treated with drug-
eluting stents, and completed at least 17 months 
of follow-up (the minimum window allowed for 
the 18-month postrandomization visit) or had a 
moderate or severe bleeding event. Bleeding events 
are presented as binary rates. The hazard ratio for 
moderate or severe bleeding is also presented as 
a post hoc descriptive analysis.
To account for missing data, we repeated the 
treatment comparisons with data from all patients 
who underwent randomization using multiple-
imputation19 logistic-regression modeling, with 
baseline covariates (50 imputations) for missing 
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Figure 2. Cumulative Incidence of Stent Thrombosis, According to Study 
Group.
Cumulative incidence curves are shown for the primary efficacy end point 
of probable or definite stent thrombosis, as assessed according to the cri-
teria of the Academic Research Consortium, in the intention-to-treat popu-
lation. Randomization occurred at 12 months after stenting. The primary-
analysis period was the period from month 12 to month 30 after percutaneous 
coronary intervention (i.e., the 18 months after randomization, during 
which subjects received the randomized study drug). Patients were fol-
lowed for an observational period of an additional 3 months after discon-
tinuation of the study drug (i.e., to 33 months after enrollment and 21 
months after randomization). P values were calculated with the use of a 
stratified log-rank test. The number at risk was defined as the number of 
patients who had not had the event of interest and who were available for 
subsequent follow-up. The final 33-month assessment visit took place be-
tween 20 and 21 months after randomization. The figure shows the num-
bers at risk at the end of that period (i.e., 21 months after randomization). 
The numbers at risk at the start of that period (i.e., 20 months after ran-
domization) were 4438 in the group that had been assigned to continued 
thienopyridine therapy versus 4362 in the group that had been assigned to 
placebo. The inset shows the same data on an enlarged y axis.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on April 20, 2015. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 371;23 nejm.org december 4, 20142162
data on the primary end points. We also assessed 
the consistency of the effect of treatment on the 
primary end points in subgroups defined accord-
ing to 14 prespecified factors assessed at baseline.
R esult s
Study Population
Between August 13, 2009, and July 1, 2011, a to-
tal of 25,682 patients at 452 sites in 11 countries 
were enrolled in the DAPT study, of whom 22,866 
received a drug-eluting stent. Among these pa-
tients, 5261 (23.0%) were not eligible for random-
ization after 12 months of follow-up, 7644 (33.4%) 
were eligible but did not undergo randomization 
(see Table S2 in the Supplementary Appendix), and 
9961 (43.6%) underwent randomization (Fig. 1). 
Among those who were eligible but did not un-
dergo randomization, the most common reason 
for not undergoing randomization was with-
drawal of consent during the year between en-
rollment and randomization (76.0%).
The baseline characteristics of the patients 
who were treated with drug-eluting stents and 
underwent randomization were similar in the 
two study groups (Table 1). Overall, 26.0% pre-
sented with acute myocardial infarction, and 
50.9% had at least one clinical or lesion-related 
risk factor for stent thrombosis (Table S1 in the 
Supplementary Appendix). The rates of discon-
tinuation of the study drug did not differ sig-
nificantly at 30 months between the group that 
continued thienopyridine therapy and the group 
that received placebo (21.4% and 20.3%, respec-
tively; P = 0.18).
Efficacy End Points
During the period from month 12 to month 30 
(the primary-analysis period), among all patients 
who underwent randomization, the group that 
continued thienopyridine, as compared with the 
group that received placebo, had a significantly 
lower cumulative incidence of stent thrombosis 
(0.4% vs. 1.4%; hazard ratio, 0.29 [95% confi-
dence interval {CI}, 0.17 to 0.48]; P<0.001) and of 
major adverse cardiovascular and cerebrovascular 
events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 
0.59 to 0.85]; P<0.001) (Table 2 and Fig. 2 and 3). 
Continued thienopyridine therapy was associated 
with a lower cumulative incidence of myocardial 
infarction than was placebo (2.1% vs. 4.1%; haz-
ard ratio, 0.47 [95% CI, 0.37 to 0.61]; P<0.001) 
(Fig. S1 in the Supplementary Appendix); myo-
cardial infarction that was not related to stent 
thrombosis (1.8% vs. 2.9%; hazard ratio, 0.59; 
P<0.001) accounted for 55% of the treatment ben-
efit. The two groups had similar rates of death 
from cardiac causes (0.9% and 1.0%, respectively; 
P = 0.98), death from vascular causes (0.1% in each 
group, P = 0.98), and stroke (0.8% and 0.9%, re-
spectively; P = 0.32). The rate of death from any 
cause was 2.0% with continued thienopyridine 
therapy and 1.5% with placebo (hazard ratio, 1.36 
[95% CI, 1.00 to 1.85]; P = 0.05) (Fig. S2 in the 
Supplementary Appendix). The results after mul-
tiple imputation were consistent with those from 
the primary analysis (hazard ratio for stent 
thrombosis, 0.27; P<0.001; and hazard ratio for 
major adverse cardiovascular and cerebrovascu-
lar events, 0.77; P = 0.002) (Table S3a in the Sup-
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Figure 3. Cumulative Incidence of Major Adverse Cardiovascular and Cere-
brovascular Events, According to Study Group.
Cumulative incidence curves are shown for the primary effectiveness out-
come of major adverse cardiovascular and cerebrovascular events (a com-
posite of death, myocardial infarction, or stroke) in the intention-to-treat 
population. P values were calculated with the use of the stratified log-rank 
test. The number at risk was defined as the number of subjects who had 
not had the event of interest and who were available for subsequent follow-
up. The numbers at risk at the start of final 33-month visit (i.e., 20 months 
after randomization) were 4336 in the group that had been assigned to 
continued thienopyridine therapy and 4217 in the group that had been as-
signed to placebo. The inset shows the same data on an enlarged y axis.
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plementary Appendix), as were the findings when 
the analysis period included the 3 months after 
discontinuation of the study drug (Table S4 in 
the Supplementary Appendix).
Safety End Points
The rate of moderate or severe bleeding during 
the primary-analysis period was significantly 
higher in the group that continued to receive thi-
enopyridine therapy than in the placebo group 
(2.5% vs. 1.6%; hazard ratio 1.61 [95% CI, 1.21 to 
2.16]; P = 0.001); treatment with thienopyridine 
did not meet the prespecified criterion for nonin-
feriority to placebo (P = 0.70) (Table 3). There was 
no significant difference between the random-
ized treatments with respect to severe bleeding 
according to the GUSTO criteria (0.81% with 
continued thienopyridine and 0.56% with place-
bo, P = 0.15) or with respect to fatal bleeding 
(type 5 bleeding) according to the BARC criteria 
(0.15% and 0.09%, respectively; P = 0.38). Addi-
tional details of the results regarding bleeding 
according to BARC subtype are provided in Table 
S5 in the Supplementary Appendix. The results 
after multiple imputation were consistent with 
those from the main analysis (between-group 
difference in the risk of moderate or severe bleed-
ing, 0.98%; P = 0.73 for noninferiority) (Table S3b in 
the Supplementary Appendix), as were the findings 
when the analysis period included the 3 months 
after study drug discontinuation (Table S6 in the 
Supplementary Appendix).
Mortality
During the primary-analysis period (month 12 to 
month 30), all-cause mortality was 2.0% in the 
group that continued to receive thienopyridine 
and 1.5% in the placebo group (hazard ratio, 
1.36; P = 0.05). During the secondary-analysis pe-
riod (month 12 to month 33), all-cause mortality 
was 2.3% versus 1.8% (hazard ratio, 1.36; P = 0.04) 
(Fig. S2 and Table S4 in the Supplementary Ap-
pendix), with the rate of death from noncardio-
vascular causes (1.1% vs. 0.6%; hazard ratio, 1.80; 
P = 0.01) accounting for the difference in rates 
between the two analysis periods. Among the 
deaths from noncardiovascular causes, bleeding-
related deaths (11 deaths in the group that con-
tinued to receive thienopyridine vs. 3 deaths in 
the placebo group, P = 0.06) were related mainly 
to fatal trauma (7 deaths vs. 2 deaths, P = 0.07). 
The number of cancer-related deaths differed sig-
nificantly between the groups (31 vs. 14, P = 0.02) 
and was mediated by bleeding in the case of 
three patients in the thienopyridine group (Table 
S7 in the Supplementary Appendix).
Table 3. Bleeding End Point during Month 12 to Month 30.*
Bleeding Complications
Continued  
Thienopyridine 
(N = 4710)
Placebo
(N = 4649) Difference
Two-Sided  
P Value  
for Difference
no. of patients (%)
percentage points  
(95% CI)
GUSTO severe or moderate† 119 (2.5) 73 (1.6) 1.0 (0.4 to 1.5) 0.001
Severe 38 (0.8) 26 (0.6) 0.2 (−0.1 to 0.6) 0.15
Moderate 81 (1.7) 48 (1.0) 0.7 (0.2 to 1.2) 0.004
BARC type 2, 3, or 5 263 (5.6) 137 (2.9) 2.6 (1.8 to 3.5) <0.001
Type 2 145 (3.1) 72 (1.5) 1.5 (0.9 to 2.1) <0.001
Type 3 122 (2.6) 68 (1.5) 1.1 (0.6 to 1.7) <0.001
Type 5 7 (0.1) 4 (0.1) 0.1 (−0.1 to 0.2) 0.38
* The primary safety end point was moderate or severe bleeding as assessed according to the Global Utilization of Strep-
tokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. The one-sided test of noninferiority 
(based on a noninferiority margin of 0.8%) was calculated according to the Farrington–Manning approach. Only pa-
tients who could be evaluated were included in this analysis (i.e., patients whose last contact date was ≥510 days after 
randomization or who had any adjudicated bleeding event at or before 540 days). Patients could have had more than 
one bleeding episode. The secondary analysis of bleeding, as assessed according to the criteria of the Bleeding Aca-
demic Research Consortium (BARC), is shown according to subtype in Table S5 in the Supplementary Appendix.
† One-sided P = 0.70 for noninferiority.
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Among patients with a history of cancer at 
the time of enrollment in the study, 22 more pa-
tients were randomly assigned to the thienopyri-
dine group than to the placebo group (Table S8 
in the Supplementary Appendix), and a blinded 
review of cancer-related deaths identified a be-
tween-group imbalance in the number of pa-
tients who underwent randomization in whom 
cancer had been diagnosed before enrollment (8 
vs. 1) (Table S9 in the Supplementary Appendix). 
When these patients were excluded in a post hoc 
sensitivity analysis, the differences in mortality 
were no longer significant (Table S10 in the 
Supplementary Appendix).
Additional Analyses
The effect of continued thienopyridine therapy 
versus placebo on the rates of the primary end 
points and on the rate of myocardial infarction 
was consistent across most subgroups (Fig. S3 in 
the Supplementary Appendix). Hazards after dis-
continuation of thienopyridine therapy are provided 
in Table S11 in the Supplementary Appendix.
Discussion
Among patients receiving drug-eluting coronary 
stents, continued treatment with thienopyridine 
and aspirin, as compared with aspirin alone, be-
yond 1 year reduced the risk of stent thrombosis 
and of major adverse cardiovascular and cerebro-
vascular events. This treatment benefit was driv-
en by concurrent reductions in myocardial in-
farction related to the stent and occurring in 
other locations. A longer duration of thienopyri-
dine treatment was associated with a greater risk 
of bleeding, although severe or fatal bleeding 
was uncommon and the rate did not differ sig-
nificantly between the study groups.
The DAPT study included a large proportion 
of patients who had risk factors for stent throm-
bosis, including many who had received a stent 
for treatment of a myocardial infarction. Across 
almost all patients and lesion types, continued 
thienopyridine therapy was associated with reduc-
tions in the risk of both coprimary end points. In 
previous studies, different stents20,21 and P2Y12 
inhibitors22 have been associated with varied 
rates of stent thrombosis and myocardial infarc-
tion; in this study, the use of thienopyridine 
beyond 1 year reduced the risks of both out-
comes across all stent and drug types. Although 
the results of previous studies vary with respect 
to the risk of discontinuation of thienopyridine 
after 6 months,10-13,23,24 the current study detect-
ed an increased risk of myocardial infarction 
(both stent-related and non–stent-related) in both 
study groups during the first 3 months after dis-
continuation. Future evaluation of thienopyri-
dine therapy with an aim toward reducing the 
risks of cardiovascular events beyond the duration 
of this study may be warranted.
An unexpected finding was that the number 
of deaths from any cause during the treatment 
period was higher in the group that continued to 
receive thienopyridine than in the group that 
received placebo, a difference that was driven by 
an increase in the number of deaths from non-
cardiovascular causes in the thienopyridine group. 
The rate of diagnosis of cancer did not differ 
significantly after randomization; however, there 
were more cancer-related deaths among patients 
treated with continued thienopyridine than among 
those who received placebo, a finding that may 
have reflected a chance imbalance in patients 
with known cancer before enrollment. Although 
one study comparing long-term thienopyridine 
therapy with placebo in patients with lacunar 
stroke identified an unexpected increase in mor-
tality,25 other large, randomized studies involv-
ing patients with coronary artery disease have 
not identified either increased or decreased risks 
of death.26-28
Several limitations of the study should be 
considered. First, only patients who were adher-
ent to therapy and who did not have a major 
adverse cardiovascular or cerebrovascular event, 
stent thrombosis, or moderate or severe bleeding 
in the first year underwent randomization, a 
study design that may have selected for patients 
who were at lower risk for late adverse events. 
Second, although we did not quantify the net 
effect of ischemic and bleeding events, a deci-
sion analysis suggests that small absolute differ-
ences in the rates of cardiovascular events may 
be sufficient29 to counterbalance bleeding risks. 
Third, although the study included four different 
metal-platform, durable polymer, drug-eluting 
stents and two platelet P2Y12 inhibitors, wheth-
er the treatment benefits observed will be gener-
alizable to other stent types30,31 or non-thieno-
pyridine P2Y12 inhibitors32,33 is unknown. In 
addition, since patients were not randomly as-
signed to a specific thienopyridine drug or stent 
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type, direct comparisons between different stent 
types or drugs may be confounded, and within-
subgroup estimates of treatment effect may be 
underpowered.
In conclusion, among patients treated with 
drug-eluting stents, continuation of thienopyri-
dine-plus-aspirin therapy, as compared with as-
pirin therapy alone, beyond 1 year reduced the 
risks of ischemic events. The reduction in the risk 
of ischemic events was consistent across stent 
type and specific thienopyridine drug used and 
was evident regardless of the risk of stent throm-
bosis. The clinical benefit of extended thieno-
pyridine treatment was tempered by an increase 
in bleeding events.
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